Articles tagged with Monoclonal Antibodies
A randomized controlled trial found that both total ankle replacement and ankle fusion improve quality of life and have similar clinical scores in patients with end-stage ankle osteoarthritis. However, TAR is associated with greater wound-healing complications and nerve injuries, while AF is linked to more blood clots and nonunion of t...
Researchers report positive results from the first placebo-controlled trial of anifrolumab, a human monoclonal antibody targeting type I interferon receptor in patients with lupus. Treatment with anifrolumab was well-tolerated and sustained reduction in lupus disease activity.
Researchers identified Spns2, an S1P transporter, as a novel drug target for Multiple Sclerosis treatment. Targeting this protein may improve safety profiles and reduce side effects associated with current therapies.
Researchers used monoclonal antibodies to suppress the immune system in mice, tracking human neural stem cell survival using luciferase. The study reveals that monoclonal antibody-mediated immunosuppression enabled long-term survival of transplanted human neural stem cells in mouse brains for at least six to eight months.
Idiopathic plasmacytic lymphadenopathy (IPL) has been confirmed as a distinct clinicopathologically uniform disease, which can be reclassified into an independent subtype of idiopathic multicentric Castleman disease (iMCD). IPL showed greater plasmacytosis and hyperplastic germinal centers compared to non-IPL groups.
A monoclonal antibody was found to be up to 88.2% effective at preventing malaria infection in healthy, non-pregnant adults during a six-month malaria season in Mali, Africa. The study suggests that this antibody could complement other measures to protect vulnerable groups from seasonal malaria.
Researchers developed investigational monoclonal antibodies targeting EBV's gH and gL proteins, blocking infection in human cells and providing nearly complete protection against EBV infection in mice. The findings highlight viable vaccine targets and potential treatment options for immunocompromised patients.
Researchers have isolated an effective monoclonal antibody that targets heroin, blocking its painkilling effect and overdose deaths in mice. The findings suggest that targeting heroin itself is more effective than its metabolites, paving the way for a new therapy.
A study reveals that BA.2.75.2, a new Omicron sublineage, largely evades neutralizing antibodies and is resistant to several monoclonal antibody treatments, posing an increased risk of SARS-CoV-2 infections this winter.
A new approach to allergy treatment has shown promise in reducing symptoms of allergic rhinitis by 36% after just one year of treatment. The combination of a monoclonal antibody with cat allergy shots was found to be more effective than allergy shots alone in providing long-lasting symptom relief.
Researchers have designed a smart cell-based delivery system to treat Alzheimer's disease by targeting multiple pathologies, reducing the risk of side effects. The system uses bio-synthesizable drugs and immune cells to deliver combination therapy that addresses all pathologies in a targeted manner.
A new study found that fewer Asian, Black, and Hispanic patients qualify for anti-amyloid monoclonal antibody treatments, which may slow Alzheimer's progression. The treatment's effectiveness depends on the presence of amyloid plaques, with lower incidence in minorities.
Researchers at UC Davis aim to develop monoclonal antibodies that can bind to specific ion channels in nerve cells, inhibiting pain signal transmission. The goal is to create a monthly, non-addictive pain medication to replace opioids, which can lead to addiction.
A new biologic drug has been found to be highly effective in reducing the signs and symptoms of moderate-to-severe eczema in infants and young children. The study showed that more than half of treated children experienced a 75% reduction in eczema symptoms, leading to improved sleep and increased ability to lead normal lives.
Physician-scientists at Beth Israel Deaconess Medical Center found that despite FDA deauthorization, a large number of doses of ineffective COVID-19 treatments were administered to patients in 2022, with wide variability by state. The study highlights the need for improved transparency and regulation of COVID-19 therapies.
A large number of patients received anti–SARS-CoV-2 monoclonal antibodies despite FDA deauthorization due to their limited effectiveness against the Omicron variant. This widespread use resulted in significant Medicare spending, estimated at over $71 million.
Researchers at Tufts University have developed a novel mRNA-based approach to generate complex antibodies in muscle cells, which can be used to treat various diseases including botulism and cancer. The technique has shown promising results in neutralizing lethal doses of botulinum neurotoxins in mice.
The AABB has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma, recommending its use for nonhospitalized patients at high risk for disease progression. The guidelines suggest that CCP is most effective when transfused with high neutralizing titers early after symptom onset.
A Phase 1 clinical trial found a monoclonal antibody to be highly protective against malaria in US adults. L9LS was administered subcutaneously and fully protected 88% of participants from infection.
Researchers developed a monoclonal antibody that binds E-cadherin, strengthening cell adhesion and preventing cancer metastasis. The antibody, 19A11, has two binding modes that increase adhesive strength through salt bridge formation.
A study by Goethe University Frankfurt found that antibodies against Omicron variants BA.1 and BA.2 decline rapidly, even after a second vaccination or booster shot, offering limited protection against infection.
Researchers discovered a potent universal coronavirus therapy that targets the S2 stalk region of the viral spike protein, highly conserved among beta-coronaviruses. The monoclonal antibody protected against infections when given as an intraperitoneal injection or nasal dose in animal experiments.
Researchers aim to develop a gene therapy that could suppress HIV replication and eliminate the need for life-long antiretroviral therapy. The study uses an AAV vector to produce leronlimab, a monoclonal antibody blocking HIV entry into immune cells.
Researchers at USAMRIID have demonstrated the use of messenger RNA (mRNA) to develop treatments for infectious diseases. The study found that administering mRNAs encoding monoclonal antibodies targeting poxviruses resulted in significant systemic levels of functional antibodies, offering potential for rapid response to disease outbreaks.
A Mayo Clinic study of 10,775 high-risk adult patients during the COVID-19 delta surge found that treatment with anti-spike neutralizing monoclonal antibodies led to low rates of severe disease, hospitalization, and mortality. The rates were lowest for patients treated with sotrovimab, with only 1.2% developing severe disease.
Researchers analyzed antibodies to internal and surface proteins of SARS-CoV-2, finding that profiles of internal proteins predicted survival outcomes as well as those for surface proteins. The study suggests targeting other parts of the virus could enhance COVID-19 vaccines and therapies.
Scientists at Institut Pasteur developed potent neutralizing antibodies from convalescent COVID-19 individuals effective against various SARS-CoV-2 variants. These human antibodies are promising candidates for immunotherapies to prevent severe forms and/or treat COVID-19 in immunocompromised patients.
Researchers have identified two broadly neutralizing antibodies that can effectively neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The antibodies, Cv2.1169 and Cv2.3194, were found to be fully active against Alpha, Beta, Gamma, and Delta variants.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
Researchers developed an antibody cocktail effective against a Hendra virus variant, neutralizing its ability to mutate and evade recognition. The combination of four antibodies leaves the virus with minimal ability to further evolve, providing significant protection against this global biosecurity threat.
Researchers at UC San Diego describe the underlying signaling pathway that causes PAH and a novel monoclonal antibody therapy that blocks abnormal blood vessel formation. The study reveals two opposing roles of NOTCH ligands and opens a door to a potentially new treatment for PAH.
A UCLA-led team found that an abnormally suppressed immune system, not a persistently hyperactive one, may be to blame for some cases of long COVID-19. The study suggests boosting immunity in those individuals could be a treatment option.
Researchers at Charité, MDC, and FU Berlin have studied the mechanisms of action of antibody and dexamethasone treatments for COVID-19. They found that combination therapy is more effective in reducing viral activity and inflammation in lung tissue, suggesting a potential game-changer in treating severe cases.
Researchers evaluated monoclonal antibody administration methods and their impact on COVID-19 hospitalization and death rates. The study found no significant difference in effectiveness between injection and intravenous administration, suggesting that injection could expand outpatient treatment capacity.
Researchers studied the sensitivity of Omicron BA.1 and BA.2 to nine monoclonal antibodies, finding reduced neutralization activity against newer variants. The study suggests that treatments may be less clinically effective against Omicron infection than against Delta variant.
Researchers found that combining durvalumab with novel agents like oleclumab and monalizumab increased major pathological response rates compared to solo durvalumab. The study also identified key immune cell signatures associated with treatment outcomes.
Researchers at Yale have identified a remdesivir-resistant variant of the SARS-CoV-2 virus in an immunocompromised patient. The discovery raises concerns about drug resistance in COVID-19 patients, particularly those with weakened immune systems.
Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.
A study found that double vaccinated individuals generate a potent and broad neutralizing antibody response after a delta breakthrough infection. This response provides protection against current variants of concern, including omicron.
Researchers have developed a monoclonal antibody called PRN100, which showed safe and encouraging results in treating Creutzfeldt-Jakob disease (CJD) in six patients. While the findings are preliminary and require further studies, they offer new prospects for this rare and fatal disease.
Researchers found that mRNA vaccines lose effectiveness against all three Omicron subvariants, BA.1, BA.1.1, and BA.2, while only bebtelovimab remains effective as a treatment. The study highlights the need for booster shots to sustain immunity.
A computational study finds that Omicron's spike protein has evolved to evade multiple classes of antibodies targeting SARS-CoV-2, even those from vaccinated individuals and monoclonal antibody treatments. The study suggests vaccines still offer protection due to the development of T cell immunity.
The Omicron variant is more transmissible than the Delta variant, spreading to individuals with two vaccine doses and previously infected individuals. A booster dose of Pfizer or AstraZeneca vaccine significantly increases antibody levels that can neutralize Omicron.
A new study finds that the Omicron variant can evade immunity from previous infections and vaccines, with antibodies from double-vaccinated individuals showing reduced neutralizing activity. The study suggests the need for new vaccines and treatments to combat evolving variants.
Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.
The Liberty Asthma VOYAGE trial found that dupilumab significantly reduced the rate of severe exacerbations by nearly 60% and improved lung function and asthma control in children ages 6 to 11. Dupilumab was also shown to be safe, with minimal adverse reactions.
A new rapid test developed by Duke University researchers can measure patient immunity against multiple COVID-19 variants like Omicron and Delta. The CoVariant-SCAN test uses a polymer brush coating to detect neutralizing antibodies, allowing for quick and accurate assessment of antibody effectiveness.
Researchers at the Ragon Institute of MGH, MIT and Harvard have developed a new anti-malarial antibody that provides significant protection against malaria, outperforming existing best-in-class antibodies. The breakthrough could lead to improved distribution of monoclonal antibodies in endemic countries.
Researchers developed a viral panel that enables simultaneous testing for SARS-CoV-2 and common respiratory viruses, providing insight into coinfections and viral spread. The tool helps predict and mitigate future outbreaks by tracking novel viral variants and their patterns of spread.
A new study found that monoclonal antibodies protected aged, diabetic rhesus macaque monkeys from SARS-CoV-2 disease by reducing signs of inflammation. The treatment prevented viral RNA in the cerebrospinal fluid and infiltration of activated immune cells, suggesting a potential preventative measure for elderly residents during outbreaks.
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
A new protocol combining patient monitoring and monoclonal antibody therapy reduced hospitalizations by half and deaths to zero for eligible patients. The study, conducted at Keck Medicine of USC, shows improved outcomes among liver and kidney transplant recipients with COVID-19.
Scientists have discovered antibodies that block the SARS-CoV-2 virus from entering cells in preclinical models. The discovery paves the way for clinical trials of monoclonal antibody treatments to prevent severe COVID-19 infection, and could provide immediate protection against the virus.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
Researchers compared COVID-19 treatment outcomes among high-risk Native American patients who received versus did not receive monoclonal antibodies. The study found significant disparities in treatment response and mortality rates among this population.
A Vanderbilt University Medical Center technology has led to the discovery of an 'ultra-potent' monoclonal antibody that neutralizes SARS-CoV-2 and its variants. The antibody's unique characteristics make it a valuable addition to therapeutic candidates.
A team of MIT engineers has developed a drug delivery capsule that can inject large quantities of monoclonal antibodies and other proteins into the stomach lining after being swallowed. The capsule overcomes a major challenge in delivering these drugs orally, which are usually administered via injections.
Researchers developed a liquid-injecting self-orienting millimeter-scale applicator (L-SOMA) that administers typically injected liquid medications orally. In large animal preclinical models, the technology delivered four commonly injected medications with comparable results to injections.
A Mayo Clinic study found that a combination of casirivimab and imdevimab reduced hospitalization rates among high-risk patients with mild to moderate COVID-19 by 60%–70%. The treatment allowed these patients to recover safely at home.
Researchers at UNC Chapel Hill engineered ultra-potent antibodies that effectively trapped and blocked over 99.9% of human sperm during animal testing. The promising results suggest an alternative non-hormonal option to prevent pregnancy may be available.